Anidulafungin

Drug Profile

Anidulafungin

Alternative Names: Ecalta; ECB; Eraxis; LY303366; PF-3910960; V-echinocandin; VEC; VER 002; VER-02

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Pfizer
  • Class Antifungals; Cyclic peptides
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Candidiasis

Highest Development Phases

  • Marketed Candidaemia; Candidiasis
  • No development reported Aspergillosis
  • Discontinued Pneumocystis pneumonia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Aug 2015 Phase III development in Candidiasis/Candidaemia (In children, In adolescents) is ongoing in USA, Brazil, Canada, Greece, Germany, France, Portugal, Spain, Italy, South Korea, Russia and Taiwan (NCT00761267)
  • 04 Aug 2015 No recent reports on development identified - Phase-III for Aspergillosis (Combination therapy) in USA, Canada, Singapore, Switzerland, South Korea, Brazil, Thailand, European Union, Turkey and Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top